381 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Buy
Article Searches
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2018 Update https://seekingalpha.com/article/4215760-tracking-ken-fishers-fisher-asset-management-portfolio-q3-2018-update?source=feed_all_articles Oct 30, 2018 - Fisher’s 13F portfolio value increased from $77.02B to $82.37B in Q3 2018.Amazon.com, Apple Inc., Visa Inc., Microsoft, and Alibaba Group Holdings are the largest five individual stock positions.Fishe
10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends https://seekingalpha.com/article/4211834-10-safer-dividend-healthcare-wallstars-gain-12minus-23-percent-per-broker-october-targets?source=feed_all_articles Oct 16, 2018 - October's top net gain safer Healthcare WallStar is AbbVie. Its projected 23% net gain was 2.3% better than Sanofi's, and 3.4% more than Grifol's result per analyst targets of 10/12/18.WallStars all s
Healthcare 16-24% Target Net Gains Pace WallStars For October https://seekingalpha.com/article/4211623-healthcare-16minus-24-percent-target-net-gains-pace-wallstars-october?source=feed_all_articles Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
PFE or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/327938/pfe-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC--327938 Oct 15, 2018 - PFE vs. NVO: Which Stock Is the Better Value Option?
Catalyst Biosciences: Rare Risk/Reward Opportunity https://seekingalpha.com/article/4211525-catalyst-biosciences-rare-risk-reward-opportunity?source=feed_sector_healthcare Oct 14, 2018 - Catalyst Biosciences is a micro-cap company focused on subcutaneous hemophilia treatments, and it appears that investors don’t buy the growth story.Price to tangible book value ratio is 1, even consid
Novo Nordisk: Type 1 Diabetes Treatments To Boost Growth https://seekingalpha.com/article/4209222-novo-nordisk-type-1-diabetes-treatments-boost-growth?source=feed_sector_healthcare Oct 01, 2018 - Novo Nordisk's Tresiba basal insulin was approved for the treatment of type-1 diabetes in Canadian children.Type-1 diabetes is rarer than type-2 diabetes, but it is still a growing market, with total
Is Now A Good Time To Buy Amgen? https://seekingalpha.com/article/4207875-now-good-time-buy-amgen?source=feed_sector_healthcare Sep 24, 2018 - Amgen is a high-quality business generating strong cash flows.Valuation is fairly reasonable.Earnings expectations are increasing.Winners tend to keep on winning in the stock market, and Amgen is deli
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff http://www.zacks.com/stock/news/323818/novo-nordisk-to-restructure-rd-unit-lay-off-400-staff?cid=CS-ZC-FT-323818 Sep 19, 2018 - Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
3 High-Quality Biotech Companies for 4th Quarter http://www.gurufocus.com/news/740841/3-highquality-biotech-companies-for-4th-quarter Sep 17, 2018 - 3 High-Quality Biotech Companies for 4th Quarter, Stocks: BIIB,GILD,NVO,BRK.A,BRK.B,AMGN,CELG, Warren Buffett, release date:Sep 17, 2018
36 'Safer' Dividend Healthcare WallStars For September https://seekingalpha.com/article/4205942-36-safer-dividend-healthcare-wallstars-september?source=feed_all_articles Sep 12, 2018 - Gilead took September's net gain safer Healthcare WallStar top spot. Its projected 21.82% net gain was 3% better than AbbVie's, and 29% more than Grifol's result, per analyst targets 9/10/18.WallStars

Pages: 12345678...39

<<<Page 3>